Head-to-head evidence
HM15211 vs NNC0662-0419
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline
HM15211
Developed by Hanmi Pharmaceutical
NCT03374241 · Phase 1 · completed
The study was randomized, blinded and placebo-controlled, a solid safety-study design, but its only primary measure was a count of adverse events rather than a clinical or weight-related efficacy outcome, and no statistical test was applied to those counts.
NNC0662-0419
Developed by Novo Nordisk
NCT06737536 · Phase 1 · completed
Participants were randomly assigned to drug or placebo under double-blind conditions across ascending-dose cohorts, a sound early-safety design, but the primary measure was the number of adverse events rather than a weight or clinical outcome, and results have not yet been reported.
Next expected readout: December 2026 · NCT07184632 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HM15211's landscape · NNC0662-0419's landscape